|   From the Trenches

Life After ECHO-301: Lessons Learned About Modulating IDO/TDO To Treat Cancer


Last week we learned about the failure of the much anticipated ECHO-301/KEYNOTE-252 trial that studied the IDO inhibitor epacadostat in combination with pembrolizumab in advanced melanoma. The results were a surprise to some, anticipated by others, and either way a bad outcome for IDO1 inhibitors, Incyte, and others heavily invested in IDO inhibition as a therapeutic approach. More significantly, it was a disappointment for cancer patients and their families looking for the next generation of immunotherapies to improve patient outcomes.

This blog was written by Mark Manfredi, CEO of Kyn Therapeutics and former Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. 

Read more.